Tocilizumab prevents renal function of a patient with diabetic kidney disease: case report

Figures & data

Table 1. Laboratory findings.

		Case	Normal range			Case	Normal range
White blood cell	/μL	10300	3200–7900	Ca	mg/dL	9	8.7–10.1
Red blood cell	10^6/μL	4.16	4.21–5.48	P	mg/dL	3.5	2.8–4.6
Haemoglobin	g/dL	12.8	11.3–15.0	Bil	mg/dL	0.4	0.3–1.1
Haematocrit	%	40.2	34.0–46.3	TSH	μU/mL	3.245	0.500–5.00
Platelet	10^3/μL	198	155–350	Free T4	ng/dL	0.94	0.90–1.70
Total protein	g/dL	6.8	6.9–8.4	CRP	mg/dL	0.6	0.0–0.3
Albumin	g/dL	3.5	3.9–5.2	ESR	mm	49	<10
AST	IU/L	22	13–33	IgG	mg/dL	974	870–1700
ALT	IU/L	16	117–350	IgA	mg/dL	279.8	110–410
LDH	IU/L	238	119–229	IgM	mg/dL	62.3	35–220
ALP	IU/L	185	117–350	ANA	1:n	11.5	<40
γGTP	IU/L	93	9–109	RF	U/mL	41	0–15
Amylase	IU/L	109	47–127	Anti-CCP antibody	U/mL	>5000	<5
Urea nitrogen	mg/dL	35	8–21	MMP-3	μg/mL	376.3	36.9–121.0
Creatinine	mg/dL	1.9	0.46–0.78	MPO-ANCA	EU	<10	<20
eGFR	mL/min/1.73	29		PR3-ANCA	EU	<10	<10
Uraemic acid	mg/dL	6.4	2.5–7.0	Urinalysis
HbA1c	%	7.3	4.6–6.2	pH		1.01
Triglyceride	mg/dL	152	30–150	Red blood cell		Negative	Negative
Total cholesterol	mg/dL	265	122–240	Albumin	mg/dL	22	<30
Na	mmol/L	142	139–146	Protein	g/day	0.04	<0.10
K	mmol/L	5.1	3.7–4.8	β2MG	μg/day	32	30–370
Cl	mmol/L	108	101–109	BJP		Negative	Negative

ANA: antinuclear antibody; RF: rheumatoid factor; MMP-3: matrix metalloprotease-3; MPO-ANCA: myeloperoxidase-anti-neutrophil cytoplasmic antibody; PR3-ANCA: serine proteinase3-anti-neutrophil cytoplasmic antibody; anti-CCP antibody: anti-cyclic citrullinated peptide antibody; β2MG: β2-microglobulin; BJP: Bence Jones protein.

Figure 1. Clinical course. BP: blood pressure; BUC: bucillamine; MTX: methotrexate; PSL: prednisolone.